TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06739031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEF Treatment
Description: PEF Energy ablation of lung tumors
Study: NCT06737770

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osseointegrated surgery for transfemoral amputation
Description: osseointegrated surgery for transfemoral amputation
Study: NCT06739161

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sintilimab combined with chemotherapy and local treatment
Description: Treatment Regimens~①Chemotherapy: Regimen follows guideline-recommended first-line therapy for advanced gastric cancer.~②Sintilimab (200 mg) is administered with chemotherapy every 21 days. Maintenance immunotherapy continues for up to 1 year after chemotherapy.~③Local Treatment: Performed during cycles 3-8 of immunochemotherapy. Radiotherapy is preferred, using a combination of high- and low-dose fractionation, tailored to tumor location, size, and proximity to critical organs.~Alternative local treatments, such as radiofrequency ablation or surgery, may be used if suitable.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab combined with chemotherapy only
Description: Treatment Regimens ①Chemotherapy: Regimen follows guideline-recommended first-line therapy for advanced gastric cancer.~②Sintilimab (200 mg) is administered with chemotherapy every 21 days. Maintenance immunotherapy continues for up to 1 year after chemotherapy.
Study: NCT06738381

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital intervention and motivational counselling
Description: A single sesstion of motivational interviewing and access to a digital plattform for a six months period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital intervention and motivational counselling
Description: A single sesstion of motivational interviewing and access to a digital plattform for a six months period
Study: NCT04759547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: handheld ultrasound-assisted technique
Description: Ultrasound with 3D navigation function is used to determine the needle insertion point and the insertion angle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional palpation-guided technique
Description: The interspinous space is detected by palpation
Study: NCT05411978

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Idebenone+ placebo
Description: Participants will receive Idebenone 30 mg+ placebo 60 mg for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: Participants will receive Idebenone 90 mg for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo 90 mg for 12 weeks
Study: NCT06372717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-4098
Description: APL-4098 is administered orally in 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine and APL-4098
Description: Azacitidine is administered at the standard dose of 75mg/m2 on Day 1 - Day 7 of each 28-day cycle; APL-4098 is administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine and APL-4098
Description: Azacitidine is administered at the standard dose of 75mg/m2 on Day 1 - Day 7 of each 28-day cycle; APL-4098 is administered orally.
Study: NCT05033002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labda Siku Moja stigma reduction intervention
Description: The Labda Siku Moja stigma reduction intervention is a tailored stigma reduction intervention for women living with HIV in Tanzania. It is comprised of five ethnodramas (video stories) culturally and linguistically relevant to the Tanzanian women living with HIV.
Study: NCT05046288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual guided tours
Description: The intervention is a participatory art-based activity which consists in MMFA virtual guided tours. Each virtual guided tour is performed with a group of 6 to 7 participants. They meet online one time per week for a 30 to 45 min of a guided tour during a 3-month period. Each tour is different and supervised by a MMFA trained guide.
Study: NCT05601713

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No cooling (control)
Description: Participants are exposed to 38°C, 35% relative humidity for 6 hours without cooling interventions (control condition). Drinking water is available ad libitum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower limb immersion
Description: Participants are exposed to 38°C, 35% relative humidity for 6 hours. For the last 40 min of each hour, participants lower limbs are immersed in cool water (\~20°C) up to the level of mid calf. Drinking water is available ad libitum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower limb immersion + neck cooling
Description: Participants are exposed to 38°C, 35% relative humidity for 6 hours. For the last 40 min of each hour, participants lower limbs are immersed in cool water (\~20°C) up to the level of mid calf. During limb immersion, a towel soaked in cool water (\~20°C) is placed around the participants neck. The towel is re-wet half way through the 40-min limb immersion. Drinking water is available ad libitum.
Study: NCT06053814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-050/NCNP-03
Description: NS-050/NCNP-03 solution for IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-050/NCNP-03
Description: NS-050/NCNP-03 solution for IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NS-050/NCNP-03 placebo-matching solution for IV infusion.
Study: NCT05402202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healing abutment with scan peg (Neoss implant system, Harrogate, England)
Description: 12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of healing abutment with scan peg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Customized healing abutment
Description: 12 participants will receive Neoss implants by fully-guided implant protocol followed by placement of customized healing abutment fabricated by intraoral scanning by scan body
Study: NCT06392438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CycloSPORINE Ophthalmic
Description: Unidose of Cequa provided without charge to the participant. 1 drop in each eye morning and evening.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: CycloSPORINE Ophthalmic
Description: Unidose of Cequa provided without charge to the participant. 1 drop in each eye morning and evening.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light
Description: Appropriate eye patches and IPL gel will be applied. 15 triggers per passage will be applied from the right temple to the left temple (7 shots from the right temple to the right nose wing, 1 on the nose bridge and 7 shots from the left nose wing to the left temple). 2 passage/session will be applied.
Study: NCT06359600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10501 tablet
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10501 tablet
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10501 tablet
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10501 tablet
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10501 tablet
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10501 tablet
Description: Administered orally
Study: NCT06392438

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Intense Pulse Light
Description: Appropriate eye patches and IPL gel will be applied. 15 triggers per passage will be applied with the plastic blocker mounted on the IPL prism from the right temple to the left temple (7 shots from the right temple to the right nose wing, 1 on the nose bridge and 7 shots from the left nose wing to the left temple). 2 passage/session will be applied.
Study: NCT05288881

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANX105
Description: Participants will receive single-ascending doses of ANX105 administered by IV infusion.
Study: NCT06359600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10501 tablet
Description: Administered orally
Study: NCT05288881

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo administered by IV infusion.
Study: NCT06359600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10501 tablet
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10501 tablet
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study: NCT04732715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CaRE Course
Description: Participants will complete the CaRE Course over a 6-8 week time period. The curriculum of the CaRE course will include topics addressing caregiving for a PLWD during a pandemic, navigating the healthcare system for a PLWD, guiding and managing daily life, and self care.
Study: NCT05745662

Intervention type: DEVICE
Intervention: Pulse Oximeter
Description: OLV-4202 pulse oximeter (SW version: 01-15)
Study: NCT05148026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin + RCA first
Description: Patients are randomized to receive this sequence of anticoagulation regimens: UFH+RCA / UFH / UFH+RCA / UFH / UFH+RCA / UFH

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin first
Description: Patients are randomized to receive this sequence of anticoagulation regimens: UFH / UFH+RCA / UFH / UFH+RCA / UFH / UFH+RCA
Study: NCT06031753

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: Only eating windows were determined to an 6 hour period, starting at 12:00hrs and ending at 18:00hrs. After that, patients in group 1 and 2 were indicated not to consume any calories. The composition of their diet was not modified, it was assessed by performing a 24-hour recall to make sure there were no significant changes in diet composition throughout the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: Only eating windows were determined to an 6 hour period, starting at 12:00hrs and ending at 18:00hrs. After that, patients in group 1 and 2 were indicated not to consume any calories. The composition of their diet was not modified, it was assessed by performing a 24-hour recall to make sure there were no significant changes in diet composition throughout the study.
Study: NCT05059899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: The exercise group will receive a 12-week home-based exercise programme, with a wearable activity watch to regulate physical activity behaviour. This group will also receive biweekly telephone calls from the investigator.
Study: NCT06432296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M701
Description: Intra-peritoneal infusion of M701 in experimental group (M701 group_

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paracentesis
Description: Puncture and Draiange of ascites from the peritoneal cavity in both experimental group and control group
Study: NCT06142084

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Protein, low bioavailability
Description: Participants will consume a protein meal consisting of cooked whole oat kernels (amount based on body weight, 0.3g of protein/kg bodyweight).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Protein, low bioavailability
Description: Participants will consume a protein meal consisting of cooked whole oat kernels (amount based on body weight, 0.3g of protein/kg bodyweight).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Protein, low bioavailability
Description: Participants will consume a protein meal consisting of cooked whole oat kernels (amount based on body weight, 0.3g of protein/kg bodyweight).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Protein, low bioavailability
Description: Participants will consume a protein meal consisting of cooked whole oat kernels (amount based on body weight, 0.3g of protein/kg bodyweight).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Protein, low bioavailability
Description: Participants will consume a protein meal consisting of cooked whole oat kernels (amount based on body weight, 0.3g of protein/kg bodyweight).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Protein, low bioavailability
Description: Participants will consume a protein meal consisting of cooked whole oat kernels (amount based on body weight, 0.3g of protein/kg bodyweight).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Protein, low bioavailability
Description: Participants will consume a protein meal consisting of cooked whole oat kernels (amount based on body weight, 0.3g of protein/kg bodyweight).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Protein, low bioavailability
Description: Participants will consume a protein meal consisting of cooked whole oat kernels (amount based on body weight, 0.3g of protein/kg bodyweight).
Study: NCT05671809

Intervention type: OTHER
Intervention: NCRT with surgery, or NCT with surgery, or surgery
Description: The eligible patients who voluntarily sign the consent form will undergo either NCRT with surgery, or NCT with surgery, or surgery according to treatment guidelines.

Intervention type: OTHER
Intervention: NCRT with surgery, or NCT with surgery, or surgery
Description: The eligible patients who voluntarily sign the consent form will undergo either NCRT with surgery, or NCT with surgery, or surgery according to treatment guidelines.

Intervention type: OTHER
Intervention: NCRT with surgery, or NCT with surgery, or surgery
Description: The eligible patients who voluntarily sign the consent form will undergo either NCRT with surgery, or NCT with surgery, or surgery according to treatment guidelines.
Study: NCT05579067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Reconstruction using an autograph of the peroneus longus tendon, folded twice.
Description: The use of a peroneus longus tendon autograft taken from the lower leg of the same limb and used as a graft to reconstruct the ACL (anterior cruciate ligament) of the knee joint.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction using an autograph of Hamstrings muscle tendons.
Description: The use of Hamstring muscle tendon autograft (Semitendinus and slender muscle) taken from the lower leg of the same limb and used as a graft to reconstruct the ACL (anterior cruciate ligament) of the knee joint.
Study: NCT05047445

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIDITY (SCOV1 and SCOV2) administered via needle-free intradermal injection
Description: Two 0.2 mg doses of the plasmid DNA vaccine SCOV1 (administered on Day 1 and Day 29), followed by two 0.2 mg doses of the plasmid DNA vaccine SCOV2 (not before Days 113 and 141 \[doses 4 weeks apart\]).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIDITY (SCOV1 and SCOV2) administered via needle-free intramuscular injection
Description: Two 1.0 mg doses of the plasmid DNA vaccine SCOV1 (administered on Day 1 and Day 29), followed by two 1.0 mg doses of the plasmid DNA vaccine SCOV2 (not before Days 113 and 141 \[doses 4 weeks apart\]).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIDITY (SCOV2 only) administered via needle-free intradermal injection to vaccine naive and/or previously vaccinated participants
Description: Two 0.8 mg doses of the plasmid DNA vaccine SCOV2 administered on Day 1 and Day 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to vaccine naive and/or previously vaccinated participants
Description: Two 4.0 mg doses of the plasmid DNA vaccine SCOV2 administered on Day 1 and Day 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIDITY (SCOV2 only) administered via needle-free intradermal injection to previously infected participants
Description: A single 0.8 mg dose of the plasmid DNA vaccine SCOV2 administered on Day 1
Study: NCT06142084

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Protein, low bioavailability
Description: Participants will consume a protein meal consisting of cooked whole oat kernels (amount based on body weight, 0.3g of protein/kg bodyweight).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Protein, low bioavailability
Description: Participants will consume a protein meal consisting of cooked whole oat kernels (amount based on body weight, 0.3g of protein/kg bodyweight).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oat Protein, low bioavailability
Description: Participants will consume a protein meal consisting of cooked whole oat kernels (amount based on body weight, 0.3g of protein/kg bodyweight).
Study: NCT05047445

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIDITY (SCOV2 only) administered via needle-free intramuscular injection to previously infected participants
Description: A single 4.0 mg dose of the plasmid DNA vaccine SCOV2 administered on Day 1
Study: NCT06161896

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool samples
Description: Analysis of microbiome, mutations, alterations in body composition and lifestyle

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool samples
Description: Analysis of microbiome, mutations, alterations in body composition and lifestyle
Study: NCT04676256

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early vitrectomy
Description: Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early vitrectomy
Description: Eyes with spontaneous vitreous hemorrhage treated with early vitrectomy (n = 63)
Study: NCT05410756

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Voice Quality and Function
Description: An acoustic voice analysis (fundamental frequency (F0), jitter, shimmer, noise to harmonic ratio (NHR), harmonic to noise ratio (HNR)) and an aerodynamic analysis (maximal phonation time (MPT)) were performed by an experienced otolaryngologist specialized in voice disorders for evaluation of objective voice quality and function. These analyses were performed on all the volunteers from both groups, and the results obtained were compared between the groups.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Voice Quality and Function
Description: An acoustic voice analysis (fundamental frequency (F0), jitter, shimmer, noise to harmonic ratio (NHR), harmonic to noise ratio (HNR)) and an aerodynamic analysis (maximal phonation time (MPT)) were performed by an experienced otolaryngologist specialized in voice disorders for evaluation of objective voice quality and function. These analyses were performed on all the volunteers from both groups, and the results obtained were compared between the groups.
Study: NCT04865874

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PPV-GDT
Description: fluid-therapy based on PPV monitoring

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zero-balance
Description: fluid-therapy based on urinary output balance
Study: NCT04884451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: Diet and physical activity modification and behavioral approach
Study: NCT05987488

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ShigETEC live, attenuated, oral vaccine
Description: Vaccine will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the vaccine 3 times 14 days apart in a dose escalating setting with two different doses.~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the vaccine 3 times 14 days apart in a dose escalating setting with three different doses.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be delivered orally.~Stage 1:~Adults (18-45 years) will intake the placebo 3 times 14 days apart~Stage 2:~Children (2-5 years), Toddlers(12-23 months), Younger children (6-11 months) will intake the placebo 3 times 14 days apart.
Study: NCT05541588

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral nerve block
Description: ultrasound guided nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral nerve block
Description: ultrasound guided nerve block
Study: NCT05358340

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic susceptibility contrast magnetic resonance imaging (DSC MRI)
Description: A dye, known as a contrast agent, will be injected through a needle that is inserted into a vein in the arm or hand. Subsequent magnetic resonance imaging will follow.
Study: NCT06184282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEBO
Description: MEBO (Julphar®, Ras Al Khaimah, United Arab Emirates) was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine gel was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.
Study: NCT06387017

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sampling
Description: blood collection